Proceeds from sale of Class A common stock and warrants, net of offering costs Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Schedule of Share Based Compensation Valuation Assumptions [Line Items] Schedule Of Share Based Compensation Valuation Assumptions [Line Items] Schedule of share based compensation valuation assumptions. Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net Change in fair value included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Less: net loss attributable to noncontrolling interest Less: Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Entity Voluntary Filers Entity Voluntary Filers Statistical Measurement Statistical Measurement [Domain] Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Non-qualified stock option awards expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Notes Payable Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Contributions made by employer Defined Contribution Plan, Employer Discretionary Contribution Amount MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Expire in 2035 to 2037 Expire In2035 To2037 [Member] Expire in 2035 to 2037. Accounts payable Accounts Payable, Current Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Contingent consideration transferred, aggregate share value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Computers and hardware Computer Equipment [Member] Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Restatement Determination Date: Restatement Determination Date [Axis] Total shares issued as of December 31, 2023 (in shares) Class Of Warrant Or Right Number Of Shares Issued For Warrants Or Rights Class of warrant or right number of shares issued for warrants or rights. Aggregate dollar value to be sold under agreement Securities Sold under Agreements to Repurchase Commitments and contingencies Commitments and Contingencies Measurement Input Price Volatility Expected volatility Measurement Input, Price Volatility [Member] Potential regulatory milestone payments based on regulatory approval Potential Regulatory Milestone Payments Receivable Upon Regulatory Approval Potential regulatory milestone payments receivable upon regulatory approval. Discount rate Notes Receivable, Discount Rate Notes Receivable, Discount Rate Insider Trading Policies and Procedures [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Proceeds from issuance of Class A common stock, net of offering costs Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Income Taxes Income Tax Disclosure [Text Block] Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Contract liabilities Increase (Decrease) in Contract with Customer, Liability Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Leases Lessee, Leases [Policy Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Audit Information [Abstract] Audit Information Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Minority Interest [Table] Noncontrolling Interest [Table] Termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Foreign withholding tax Income Tax Reconciliation Foreign Withholding Tax Income tax reconciliation, foreign withholding tax. Preferred stock par value (usd per share) Preferred Stock, Par or Stated Value Per Share Issuance of Class A common stock under LPC Agreement Issuance Of Class A Common Stock Under L P C Agreement Issuance of Class A Common Stock under LPC agreement. Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Subsequent Event Type Subsequent Event Type [Domain] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share) Earnings Per Share, Diluted Change in fair value of investments Unrealized gain (loss) on investment Unrealized Gain (Loss) on Investments Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] PEO Total Compensation Amount PEO Total Compensation Amount Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Right of purchase of common stock from issuance of private placement, wait period Right to Purchase of Common Stock from Issuance of Private Placement, Wait Period Right to Purchase of Common Stock from Issuance of Private Placement, Wait Period Prepaid Expense and Other Assets, Current [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Renewal term Lessor, Operating Lease, Renewal Term Award outstanding, beginning balance (in shares) Award outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Redeemable noncontrolling interest Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Restructuring Plan Restructuring Plan [Domain] Schedule Of Share Based Compensation Valuation Assumptions [Table] Schedule Of Share Based Compensation Valuation Assumptions [Table] Schedule Of Share Based Compensation Valuation Assumptions [Table] Reverse Stock Split Reverse Stock Split [Member] Reverse Stock Split Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Issuance of Class A Common Stock under LPC agreement (in shares) Issuance Of Class A Common Stock Under L P C Agreement Shares Issuance of Class A Common Stock under LPC agreement shares.. Granted (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value of options granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss attributable to vTv Therapeutics Inc. Net loss Net loss attributable to vTv Therapeutics Inc. Net Income (Loss) Total current liabilities Liabilities, Current Potential sales-based milestones based on tiered sales of licensed products Potential Sales Milestone Payments Receivable Potential sales milestone payments receivable. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Funding received Funding Received Funding received. Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit Liabilities and Equity [Abstract] Proceeds from sale of Class A common stock to collaboration partner, net of offering costs Proceeds From Sale Of Common Stock Proceeds From Sale Of Common Stock Letter agreement time period Letter Agreement Term Letter Agreement Term Stock repurchased during period Stock Repurchased During Period, Value Notes receivable recorded at fair value from collaboration partner Notes Receivable from Collaborators Notes Receivable from Collaborators Accrued development costs Accrued Development Costs Current Accrued development costs current. Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Cantor Fitzgerald Cantor Fitzgerald [Member] Cantor fitzgerald member. Impairment of investments in Anteris Bio, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Class B Common Stock Common Class B [Member] Total notes payable, net of current portion Notes Payable, Noncurrent Novo License Agreement Novo License Agreement [Member] Novo license agreement. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Nonmonetary Transaction Type [Axis] Nonmonetary Transaction Type [Axis] Name Measure Name Name Forgone Recovery, Individual Name Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components Equity Components [Axis] Research And Development Research Tax Credit Carryforward [Member] Financial Instruments Financial Instruments [Domain] Exercise price of warrants (usd per share) Exercise price of related warrants (usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Phase 2 MRCT Phase Two Multi Regional Clinical Trial [Member] Phase two multi-regional clinical trial. Equity Securities With Readily Determinable Fair Value [Line Items] Equity Securities With Readily Determinable Fair Value [Line Items] Equity securities with readily determinable fair value line items. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business letter agreement, maximum exercisable times Letter Agreement Warrant, Maximum Exercisable Times Letter Agreement Warrant, Maximum Exercisable Times Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Transaction Transaction [Domain] Measurement Frequency Measurement Frequency [Axis] Common stock warrants Warrant [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Instrument, Name Debt Instrument, Name [Domain] Depreciation expense Depreciation Retirement Benefits [Abstract] Retirement Benefits [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Transaction Type Transaction Type [Axis] Income Statement Location Income Statement Location [Axis] Schedule of Notes Payable Schedule of Long-Term Debt Instruments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Purchases / Issuance Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases And Issuances Fair value measurement with unobservable inputs reconciliation recurring basis warrant liability issuance. Redemption amount of noncontrolling interest Redeemable Noncontrolling Interest Temporary Equity Redemption Value Redeemable noncontrolling interest temporary equity redemption value. Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Payables and Accruals [Abstract] Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Issuance of Class A common stock under ATM offering (in shares) Issuance Of Class A Common Stock Under A T M Offering Shares Issuance Of Class A Common Stock Under ATM Offering shares, Product and Service Product and Service [Domain] Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Sale of Stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Stock options vested, fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Horizon Technology Finance Corporation and Silicon Valley Bank Horizon Technology Finance Corporation And Silicon Valley Bank [Member] Horizon Technology Finance Corporation and Silicon Valley Bank. Revenue from collaborative arrangement Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Interest expense Interest Expense Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Loss from G42 Promissory Note early redemption Gain (loss) on extinguishment of debt Gain (Loss) on Extinguishment of Debt ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative General and Administrative Expense [Member] Total property and equipment Property, Plant and Equipment, Gross Trading Arrangement: Trading Arrangement [Axis] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Current portion of operating lease liabilities Operating Lease, Liability, Current Auditor Firm ID Auditor Firm ID Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-term investments Long-Term Investments Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Issued Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Capital loss carryforward Deferred Tax Assets, Capital Loss Carryforwards Commission percent Sale of Stock, Commission Percent Sale of Stock, Commission Percent Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants Counterparty Name [Domain] Counterparty Name [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule Of Restructuring And Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Total cash and cash equivalents, beginning of year Total cash and cash equivalents, end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Percent of public float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Sale of Stock, Maximum Securities To Be Sold, Percent Of Public Float Aggregate offering price Sale Of Stock, Aggregate Offering Price Aggregate offering price. Expected life of option, in years Measurement Input, Expected Term [Member] Common stock, vote per share Common Stock Number Of Votes Per Share Common stock number of votes per share. Share price (usd per share) Sale of Stock, Price Per Share Private Placement Private Placement [Member] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Operating lease cost Operating Lease, Cost Anteris Bio, Inc. Anteris Bio Inc [Member] Anteris Bio, Inc. Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Current portion of contract liabilities Contract with Customer, Liability, Current Assumptions Used to Estimate Fair Value of Stock Option Awards Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Research and development tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Aggregate gross purchase price Sale of Stock, Consideration Received on Transaction Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Common stock options granted under the Plan Employee Stock Option [Member] Investments Investment, Policy [Policy Text Block] Percentage of employer contribution Defined Contribution Plan, Employer Matching Contribution, Percent of Match Retirement and Consulting Agreement Retirement And Consulting Agreement [Member] Retirement and consulting agreement. ATM Offering At The Market Offering [Member] At the market offering. G42 Investments G42 Investments [Member] G42 Investments Class A Common Stock Common Class A [Member] Weighted average period to recognize unrecognized share-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Stock Conversion Description Stock Conversion Description [Axis] Income Taxes [Table] Income Taxes [Table] Income taxes. Maximum Maximum [Member] Document Type Document Type Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Tabular List, Table Tabular List [Table Text Block] Domestic Tax Authority Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Collaboration Revenue and Accounts Receivable Collaboration Revenue And Accounts Receivable Policy [Policy Text Block] Collaboration revenue and accounts receivable. Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair value equity transfers in and out of level 3 instruments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Letter Agreements With MacAndrews Letter Agreements With MacAndrews [Member] Letter Agreements With MacAndrews Subsequent Event Subsequent Event [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Net operating loss carryforwards Operating Loss Carryforwards Customer Customer Concentration Risk [Member] Shares held by related party (in shares) Investment Owned, Balance, Shares Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Current deposits Deposits Assets, Current Property and equipment, estimated useful lives Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Restructuring Cost And Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Non-cash interest income Interest Income, Operating Agreement term Agreement Term Agreement term. Related Party Related Party, Type [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Class Of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] U.S. statutory tax benefit Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Partnership income (federal) not subject to tax to the Company Income Tax Reconciliation Partnership Income Federal Not Subject To Tax Income tax reconciliation partnership income federal not subject to tax. CinRx Pharma, LLC CinRx Pharma, LLC [Member] CinRx Pharma, LLC Other Commitments Other Commitments [Domain] Proceeds from issuance of private placement Proceeds from Issuance of Private Placement Statistical Measurement Statistical Measurement [Axis] Financial Instrument Financial Instrument [Axis] Noncontrolling Interest Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Receivables, fair value disclosure Receivables, Fair Value Disclosure Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] License agreement termination, period License Agreement Termination, Period License Agreement Termination, Period Increase decrease in uncertain tax position reasonably possible Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Total Shareholder Return Amount Total Shareholder Return Amount Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Newsoara Biopharma Co., Ltd. Newsoara Biopharma Co Ltd [Member] Newsoara Biopharma Co Ltd. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Private Placement Pre-Funded Warrants Private Placement Pre-Funded Warrants [Member] Private Placement Pre-Funded Warrants Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] JDRF J D R F International [Member] JDRF international. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Leases [Abstract] Leases [Abstract] Equity investment with readily determinable fair value: Equity Securities, FV-NI Assets held for sale Disposal Group, Including Discontinued Operation, Assets Schedule of Net Deferred Tax Assets/(Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Additional consulting fees Additional Consulting Fees Additional consulting fees. Counterparty Name [Axis] Counterparty Name [Axis] Warrant shares percentage issued of loan amount Warrants Shares Issued Percentage Of Loan Amount Warrants shares issued percentage of loan amount. Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Cash paid for operating lease Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Change in redemption value of noncontrolling interest Noncontrolling Interest, Change in Redemption Value PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Total notes payable Notes Payable Accrued compensation and related costs Accrued Compensation And Related Costs Accrued compensation and related costs. M&F TTP Holdings LLC M F T T P Holdings L L C [Member] M&F TTP Holdings LLC. Conversion of Stock, Name Conversion of Stock, Name [Domain] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Indefinite Indefinite [Member] Indefinite. State taxes (net of federal benefit) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock par value (usd per share) Common Stock, Par or Stated Value Per Share Maximum annual contribution per employee Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Customer [Domain] Customer [Domain] Net loss attributable to vTv Therapeutics Inc. common shareholders Net loss attributable to common shareholders of vTv Therapeutics Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Other Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument Debt Instrument [Axis] Collaborative Arrangements Collaborative Arrangement [Member] Maximum percentage of taxable income limited to offset by net operating loss carryforwads. Maximum Percentage Of Taxable Income Limited To Offset By Net Operating Loss Carryforwads Maximum percentage of taxable income limited to offset by net operating loss carryforwads. 2017 Letter Agreement Two Thousand And Seventeen Letter Agreement [Member] December two thousand and seventeen letter agreement. Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Potential milestone payment Potential Milestone Payment Potential milestone payment. Present value of lease liabilities Operating Lease, Liability Measurement Input Type Measurement Input Type [Domain] Total liabilities Liabilities 2019 Letter Agreement Two Thousand And Nineteen Letter Agreement [Member] Two thousand and nineteen letter agreement. Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Equity method investments, ownership percentage Investment Ownership Percentage Investment ownership percentage. Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block] Tabular disclosure of investment in equity security with and without readily determinable fair value. Options vested and expected to vest (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency Measurement Frequency [Domain] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Contract liabilities, net of current portion Contract with Customer, Liability, Noncurrent 2018 Letter Agreement Two Thousand And Eighteen Letter Agreement [Member] Two thousand and eighteen letter agreement. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair value of assets and liabilities measured on recurring basis table. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Related Party Transaction Related Party Transaction [Domain] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Tax benefit related to stock option awards Share-Based Payment Arrangement, Expense, Tax Benefit Number of reportable segment Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock value Common Stock, Value, Issued General and administrative General and Administrative Expense Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Potential development and regulatory milestone payments receivable. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Capital Loss Carryforward Capital Loss Carryforward [Member] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Segment and Geographic Information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Asset impairment charges Asset Impairment Charges All Individuals All Individuals [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Satisfaction of Milestone Payment Satisfaction Of Milestone Payment [Member] Satisfaction of milestone payment. Note receivable, discount paid Collaborative Arrangement, Note Receivable, Discount Paid Collaborative Arrangement, Note Receivable, Discount Paid Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Other (expense) income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Beginning balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Issuance of Class A Common Stock under CinRx purchase agreement, net of offering costs (in shares) Stock Issued During Period, Shares, Purchase Agreement Issuance of Class A Common Stock under LPC agreement shares.. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair value of assets and liabilities measured on recurring basis. Uncertain tax positions Unrecognized Tax Benefits Income Tax Authority Income Tax Authority [Axis] PEO Name PEO Name Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Concentration risk percentage Concentration Risk, Percentage Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Prepaid insurance Prepaid Insurance Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance [Abstract] Summary of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Warrant liability, related party Warranty Liability Warranty Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock Class of Stock [Axis] Change in fair value of warrants, related party Change In Fair Value Of Warrants Related Party Change in fair value of warrants related party. Interest expense Interest Expense, Other Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accrued other Other Accrued Liabilities, Current Change in fair value of consideration warrants expense Fair Value Adjustment of Warrants Furniture and office equipment Furniture and Fixtures [Member] Patent Costs Patent Costs Policy [Policy Text Block] Patent costs. Accounts payable and accrued expenses Total Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] CinRx Investment CinRx Investment [Member] CinRx Investment Total stockholders’ deficit attributable to vTv Therapeutics Inc. Beginning balance Ending balance Equity, Attributable to Parent Investment in partnerships Deferred Tax Assets, Investments Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Assumptions Used to Calculate Fair Value of Warrants Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Significant interest or penalties incurred related to income taxes Income Tax Examination, Penalties and Interest Expense Collaboration revenue recognized Contract with Customer, Liability, Revenue Recognized Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type Concentration Risk Type [Axis] Developmental And Regulatory Milestone Payment Developmental And Regulatory Milestone Payment [Member] Developmental and regulatory milestone payment. Expected life of option, in years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Measurement input Inputs utilized in the valuation of warrants Warrants and Rights Outstanding, Measurement Input Equity investment without readily determinable fair values assessed under the measurement alternative: Equity Securities without Readily Determinable Fair Value, Amount Restructuring Restructuring and Related Activities Disclosure [Text Block] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Exchange of Class B Common Stock for Class A Common Stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Collaborative arrangement, royalties receivable, period Collaborative Arrangement, Royalties Receivable, Period Collaborative Arrangement, Royalties Receivable, Period Issuance of Class A common stock under ATM offering Stock Issued During Period Under Direct Offering Value Stock issued during period under direct offering value. Equity interest received Proceeds from Interest and Dividends Received Entity Emerging Growth Company Entity Emerging Growth Company Total deferred tax assets Deferred Tax Assets, Gross Nonmonetary Transaction Type [Domain] Nonmonetary Transaction Type [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Entity public float, threshold Entity Public Float, Threshold Entity Public Float, Threshold Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] Other Indication Other Indication [Member] Other indication. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Awards outstanding, beginning balance (usd per share) Awards outstanding, ending balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Capital stock, shares authorized (in shares) Common Stock And Preferred Stock Shares Authorized Common stock and preferred stock shares authorized. Common Stock Common Stock [Member] Individual: Individual [Axis] Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Percentage of non voting economic interest by parent. City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Net Loss per Share Earnings Per Share [Text Block] Income Statement Location Income Statement Location [Domain] Proceeds from debt issuance Proceeds from Notes Payable Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Maximum funding percentage of research and development milestones. G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement Document Fiscal Year Focus Document Fiscal Year Focus Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Summary of Stock Award Activity for the Period Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Tranche One Debt Instrument Tranche One [Member] Debt instrument tranche one. Summary of Terms of Letter Agreements Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Liabilities: Liabilities, Fair Value Disclosure Warrants expiration period Warrants Expiration Period Warrants expiration period. Net loss before noncontrolling interest Net loss before noncontrolling interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Cash paid for income taxes Income Taxes Paid, Net Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Exchange of Redeemable Non controlling Interest To Class A Common Stock Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Exchange of redeemable non controlling interest to class A common stock. Summary of Compensation Expense Related to Grants of Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities, redeemable noncontrolling interest and stockholders’ deficit Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost related to non-vested share-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Restructuring costs Restructuring Costs Sale of Stock [Domain] Sale of Stock [Domain] Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected life of options in years Warrants and Rights Outstanding, Term Net deferred tax assets Deferred Tax Assets, Net Sales-based Milestones Payment Sales Based Milestones Payment [Member] Sales-based milestones payment. Warrants to purchase shares of common stock (in shares) Shares available to be issued under related warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Master Service Agreement Master Service Agreement [Member] Master Service Agreement License fee received License Fee Received License fee received. Sale of stock, consideration, receivable, term Sale Of Stock, Consideration, Receivable, Term Sale Of Stock, Consideration, Receivable, Term Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Impairment charges Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Document Information [Table] Document Information [Table] Adjustments to transaction price for performance obligations Adjustments To Transaction Price For Performance Obligations Adjustments to transaction price for performance obligations. Entity Public Float Entity Public Float Line of Credit Facility, Lender Line of Credit Facility, Lender [Domain] Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Noncontrolling interest ownership percentage Percentage Of Non Voting Economic Interest Percentage of non voting economic interest. Realized gain on sale of investment in Reneo Pharmaceuticals, Inc. Equity Securities, FV-NI, Realized Gain Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type Measurement Input Type [Axis] Current portion of notes payable Short-term financing Less: Current portion Notes Payable, Current All Adjustments to Compensation All Adjustments to Compensation [Member] Common stock outstanding Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Compensation Amount Outstanding Recovery Compensation Amount LPC Purchase Agreement L P C Purchase Agreement [Member] LPC purchase agreement. Other Commitments Other Commitments [Axis] Shares registered under the LPC agreement (in shares) Shares Registered Under The L P C Agreement Shares registered under the LPC agreement. Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Three Customers Three Customers [Member] Three Customers Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Document Information [Line Items] Document Information [Line Items] Restructuring Plan Restructuring Plan [Axis] Subsequent Event Type Subsequent Event Type [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Total Prepaid Expense and Other Assets, Current Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Warrant Liability, Related Party Warrant Liability Related Party [Member] Warrant liability, related party. Insider Trading Arrangements [Line Items] Letter Agreement Warrants Letter Agreement Warrants [Member] Letter agreement warrants. Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Increase in shares authorized (in shares) Increase In Common Stock Shares Authorized Increase in common stock shares authorized. Share price (usd per share) Specified purchase price per share (usd per share) Share Price Related Party Related Party, Type [Axis] Other income – related party Other Income Expenses Related Party The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other assets Increase (Decrease) in Other Operating Assets Maximum contribution amount to clinical trial Maximum Sponsoring Contribution Amount Maximum sponsoring contribution amount. Warrants and rights outstanding Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Equity Securities Without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Cogna Cogna [Member] Cogna Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Issuance of Class A common stock under CinRx purchase agreement, net of offering costs Stock Issued During Period, Amount, Purchase Agreement Stock Issued During Period, Amount, Purchase Agreement Cash payments Payments for Restructuring Auditor Name Auditor Name Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loan and Security Agreement Loan And Security Agreement [Member] Loan and security agreement. TD Cowen Sales Agreement TD Cowen Sales Agreement [Member] TD Cowen Sales Agreement Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Revenue recognized from change in estimated transaction prices Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Entity Central Index Key Entity Central Index Key Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Compensation expense related to share-based awards Total share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax provision Provision for income taxes Income Tax Expense (Benefit) Income Tax Authority Income Tax Authority [Domain] One Customer One Customer [Member] One Customer Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Number of operating segments Number of Operating Segments Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Charitable contributions Deferred Tax Assets, Charitable Contribution Carryforwards Lender Name Lender Name [Axis] Aggregate offering price Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Change in redemption value of noncontrolling interest Change In Redemption Value Of Noncontrolling Interest Change in redemption value of noncontrolling interest. Legal Entity Legal Entity [Axis] License And Technology Transfer Services License And Technology Transfer Services [Member] License and technology transfer services. Tax credit carryforward R&D Tax Credit carryforwards Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Repayment of notes payable Repayments of Notes Payable Tax Period Tax Period [Domain] Weighted average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Property and equipment, estimated useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Sales / Repurchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Leasehold improvements Leasehold Improvements [Member] Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Software Software Development [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Maximum research funding receivable achievement based on research and development milestones Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones Maximum research funding receivable based on achievement of research and development milestones. License and Technology Transfer Services of Chemistry and Manufacturing Know-How License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member] License and technology transfer services of chemistry and manufacturing know-how. Operating expenses: Operating Expenses [Abstract] Additional severance costs Additional Severance Costs Additional severance costs. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Proceed from sale of investments in Reneo Pharmaceuticals, Inc. Proceeds from Sale of Equity Securities, FV-NI Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Due to related parties, monthly amount Due To Related Parties, Monthly Amount Due To Related Parties, Monthly Amount Promissory note receivable Notes Receivable, Current Notes Receivable, Current Cover [Abstract] Cover [Abstract] Laboratory equipment Equipment [Member] Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Tax Period Tax Period [Axis] Prepaid - other Other Prepaid Expense, Current Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Tax Credit Carryforward, Name Tax Credit Carryforward, Name [Domain] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Unrecognized amount of transaction price allocated to performance obligation Revenue, Remaining Performance Obligation, Amount Restructuring workforce employee affected percentage Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent Employee Benefit Plan Compensation and Employee Benefit Plans [Text Block] Total operating expenses Operating Expenses Net (decrease) increase in cash, cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component Equity Component [Domain] Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited. Adjustment to Compensation: Adjustment to Compensation [Axis] Private placement pre-funded warrants, shares (in shares) Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares Common Stock, Par or Stated Value of Private Placement Pre-Funded Warrants, Shares Tranche Two Debt Instrument Tranche Two [Member] Debt instrument tranche two. Accounts and financing receivable, after allowance for credit loss Accounts and Financing Receivable, after Allowance for Credit Loss, Current Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Private placement, shares (in shares) Common Stock, Par or Stated Value of Private Placement, Shares Common Stock, Par or Stated Value of Private Placement, Shares Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Operating loss Operating Income (Loss) Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Summary of Estimated Useful Lives of Property and Equipment Property And Equipment Estimated Useful Lives Table [Table Text Block] Property and equipment estimated useful lives. Related Party Transaction Related Party Transaction [Axis] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Property and Equipment and other Long-lived Assets Property, Plant and Equipment, Policy [Policy Text Block] Ownership percentage of majority owner Ownership Percentage Of Majority Owner Ownership percentage of majority owner. Reneo Reneo Pharmaceuticals Inc [Member] Reneo Pharmaceuticals Inc. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Tax Credit Carryforward Tax Credit Carryforward [Axis] Useful Life, Lease Term [Member]